Coegin Pharma is a Nordic biotechnology company with a broad pipeline of innovative dermacosmetic products and pioneering drug candidates. Our projects have great potential to improve the quality of life for people with cosmetic challenges and for the treatment of patients with serious diseases such as cancer and diabetes complications. The strategy is to create value by developing and commercializing dermacosmetic products in partnership with significant commercial players and early handing over "first-in-class" drug candidates to larger pharmaceutical companies.

ABOUT US

Our portfolio companies

With our three portfolio companies, we have a pipeline consisting of both dermacosmetic product candidates for stimulating hair growth and drug candidates in skin cancer.

Follicum focuses on the development of a new and pioneering product line that stimulates hair growth.

Read more on follicum.com

Avexxin Oncology focuses on the development of new innovative drugs in inflammation-driven cancer.

Read more on avexxinoncology.com

Reccura Therapeutics focuses on being able to offer a unique and well-tolerated treatment for both actinic keratosis and basal cell carcinoma.

Read more on reccuratherapeutics.com

Our research

In our total project portfolio, we currently have six projects: five drug candidates and a product series in dermacosmetics. What the projects have in common is that they are based on two unique validated technology platforms resting on solid research and collaborations with pioneering and internationally recognized researchers and academics.

Latest news

Press releases

More press releases

Reports

More reports

Upcoming events

More events

Coegin News

Se all Episodes

Team Coegin

Our management team has extensive experience in drug development, commercialization and business scale-up.

meet the team
Tore Duvold

VD

Lars Bukhave Rasmussen

CFO

Berit Johansen

CSO

John Zibert

CMO